Blood pressure independent effects of nitrendipine on cardiac structure in patients after renal transplantation

Nephrology Dialysis Transplantation

Volumn 12, Issue 7, 1997, Pages 1441-1447

  Rockstroh, J K ^a,b   Schobel, H P ^a   Vogt Ladner, G ^a   Hauser, I ^a   Neumayer, H H ^a,c   Schmieder, R E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Blood pressure; Calcium channel blocker; Left ventricular hypertrophy; Renal transplantation

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; FUROSEMIDE; GLUCOSE; LIPID; NITRENDIPINE; PLACEBO; RENIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART VENTRICLE SEPTUM; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MALE; MULTICENTER STUDY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRUCTURE ACTIVITY RELATION; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADULT; AGED; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; FEMALE; HEART; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NITRENDIPINE;

EID: 0030746555     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.7.1441     Document Type: Article

References (32)

1. Messerli FH. Going to the heart of the matter. Circulation 1990; 81: 1128-1135
2. Silberberg JS, Barre PE, Prichard SS, Snidermann AD. Impact of left ventricular hypertrophy on survival of end-stage renal disease. Kidney Int 1989; 36; 286-290
3. Koren MJ, Ulin R, Laragh JH, Devereux RB. Reduction of left ventricular mass during treatment of essential hypertension is associated with improved prognosis. Am J Hypertens 1991; 4: IA (abstract)
4. Yurenev AP, Dyakonova HG, Novikov ID et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Am J Hypertens 1992; 5: 182-189
5. Koren MJ, Devereux RB, Casala PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Annals Intern Med 1991; 114: 345-352
6. Myers G, Leenen FHH, Taller J. Differential effects of felodipine and nifedipine on 24-hour blood pressure and left ventricular mass. Am J Hypertens 1995; 8: 712-718
7. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: Metaanalysis of randomized double-blind studies. JAMA 1996; 275: 1507-1513
8. Machning T, Henneke KH, Engels G et al. Nitrendipine versus captopril in essential hypertension: effects on circadian blood pressure and left ventricular hypertrophy. Cardiology 1994; 85: 101-110
9. Barenbrock M, Breuer J, Schröder K, Wagner K, Neumayer HH, Rahn KH. A study of the nephroprotective effect of nitrendipine after renal transplantation. Internat Soc Nephrol 1995; 387
10. Mann JFE, Johnson AK, Ganten D. Plasma angiotensin II: Dipsogenetic level and the angiotensin generating capacity of renin. Am J Phys 1980; 238: R372-377
11. Schmieder RE, Langenfeld MRW, Friedrich A, Schobel HP, Gatzka CD, Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human hypertension. Circulation 1996; 94: 1304-1309
12. Gatzka CD, Schmieder RE. Improved classification of dippers by individualized analysis of ambulatory blood pressure profiles. Am J Hypertens 1995; 8: 666-671
13. Gatzka CD, Schmieder RE, Schobel HP, Klingbeil AU, Weihprecht H. Improved prediction of left ventricular mass from ambulatory blood pressure monitoring using average tension-time index. J Hypertens 1993; 11(Suppl. 5): S98-S99
14. Schobel HP, Langenfeld M, Gatzka CD, Schmieder RE. Treatment and post treatment effects of alpha vs beta receptor blockers on left ventricular structure and function in essential hypertension. Am Heart J 1996; 132: 1004-1009
15. Sahn DJ, DeMaria A, Kisslo J, Weyman A (The Committee on M-Mode Standardization of the American Society of Echocardiography). Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083
16. Devereux RB, Savage DD, Sachs I, Laragh JH. Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension. Am J Cardiol 1983; 51: 171-176
17. Norusis MJ/SPSS. SPSS for Windows, professional statistics, Release 6.0. Chicago, 1993
18. Foley RN, Parfrey PS, Harriett JD et al. Clinical and echocardiographic disease in patients starting end stage renal disease therapy. Kidney Int 1995; 47: 186-192
19. Himelman RB, Landzberg JS, Simonson JS et al. Cardiac consequences of renal transplantation: changes in left ventricular morphology and function. JACC 1988; 12: 915-923
20. Lubic SP, Giacomini KM, Giacomini JC. Myocardial hypertrophy in cell culture is associated with an increased number of calcium channels. Circulation 1990; 82(Suppl. III): 142
21. Inoue I, Matsuura H, Shingu T, Kawagoe T et al. Role of intracellular cation abnormalities in development of left ventricular hypertrophy. J Cardiovasc Pharmacol 1991; 17(Suppl. 2): S107-S109
22. Gatzka CD, Schobel HP, Klingbeil AU, Neumayer HH, Schmieder RE. Normalization of circadian blood pressure profiles after renal transplantation. Transplantation 1995; 59: 1270-1274
23. Schmieder RE, Rockstroh JK, Aepfelbacher F, Schulze B, Messerli FH. Gender-specific cardiovascular adaptation due to circadian blood pressure variations in essential hypertension. Am J Hypertens 1995; 8: 1160-1166
24. Verdecchia P, Schillaci G, Guerrieri M et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-536
25. Schulte KL, Meyer-Sabellek W, Liederwald K, van Gemmeren D, Lenz T, Gotzen R. Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine. Am J Cardiol 1992; 70: 468-473
26. Gosse P, Roudaut R, Dallocchio M. Effets du vérapamil et de la nifédipine sur la pression artérielle au repos et à léffort et la masse ventriculaire gauche. Arch Mal Coeur 1992; 85: 1249-1252
27. de Simone G, Costantino G, Soro S et al. Effects of nicardipine on left ventricular hemodynamic patterns in systemic hypertension. Am J Hypertens 1989; 2: 139-145
28. Dittrich HC, Adler J, Ong J, Reitman M, Weber M, Ziegler M. Effects of sustained-release nicardipine on regression of left ventricular hypertrophy in systemic hypertension. Am J Cardiol 1992; 69: 1559-1564
29. von Karsa L, Schmieder RE, Schach S, Sterzel RB. Prevalence of ECG-LVH and other cardiovascular risk factors in 1.4 million German adults. PhD thesis, Karsa L. University, Erlangen-Nuremberg, Germany
30. Kelemen MH, Effron MB, Valenti SA, Stewart KJ. Exercise training combined with antihypertensive drug therapy. JAMA 1990; 263: 2766-2771
31. Everett AD, Tufro-McReddie A, Fisher A, Gomez A. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-β1 expression. Hypertension 1994; 23: 587-592
32. Schmieder RE, Messerli FH, Garavaglia GE, Nunez B, MacPhee AA, Re RN. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension? Am J Med 1988; 84(Suppl. 3A): 136-139